Thymalfasin for the treatment of chronic hepatitis C infection

Research output: Chapter in Book/Report/Conference proceedingConference contribution

3 Citations (Scopus)

Abstract

The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
PublisherBlackwell Publishing Inc.
Pages357-367
Number of pages11
ISBN (Print)1573317012, 9781573317016
DOIs
StatePublished - Jan 1 2007
Externally publishedYes

Publication series

NameAnnals of the New York Academy of Sciences
Volume1112
ISSN (Print)0077-8923
ISSN (Electronic)1749-6632

Fingerprint

Chronic Hepatitis C
Viruses
Hepacivirus
Infection
Ribavirin
Placebos
Therapeutics
Mexico
Viral Load
Hispanic Americans
Genotype
thymalfasin
Virus
RNA
Safety
Kinetics
Placebo

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science

Cite this

Rustgi, V. (2007). Thymalfasin for the treatment of chronic hepatitis C infection. In Annals of the New York Academy of Sciences (pp. 357-367). (Annals of the New York Academy of Sciences; Vol. 1112). Blackwell Publishing Inc.. https://doi.org/10.1196/annals.1415.034
Rustgi, Vinod. / Thymalfasin for the treatment of chronic hepatitis C infection. Annals of the New York Academy of Sciences. Blackwell Publishing Inc., 2007. pp. 357-367 (Annals of the New York Academy of Sciences).
@inproceedings{349c9dc5684d483ba7294a23a0b2e2d4,
title = "Thymalfasin for the treatment of chronic hepatitis C infection",
abstract = "The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.",
author = "Vinod Rustgi",
year = "2007",
month = "1",
day = "1",
doi = "10.1196/annals.1415.034",
language = "English (US)",
isbn = "1573317012",
series = "Annals of the New York Academy of Sciences",
publisher = "Blackwell Publishing Inc.",
pages = "357--367",
booktitle = "Annals of the New York Academy of Sciences",

}

Rustgi, V 2007, Thymalfasin for the treatment of chronic hepatitis C infection. in Annals of the New York Academy of Sciences. Annals of the New York Academy of Sciences, vol. 1112, Blackwell Publishing Inc., pp. 357-367. https://doi.org/10.1196/annals.1415.034

Thymalfasin for the treatment of chronic hepatitis C infection. / Rustgi, Vinod.

Annals of the New York Academy of Sciences. Blackwell Publishing Inc., 2007. p. 357-367 (Annals of the New York Academy of Sciences; Vol. 1112).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

TY - GEN

T1 - Thymalfasin for the treatment of chronic hepatitis C infection

AU - Rustgi, Vinod

PY - 2007/1/1

Y1 - 2007/1/1

N2 - The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.

AB - The purpose of this review article is to examine previous and ongoing studies of thymalfasin in combination with peginterferon-α2a and peginterferon-α2a plus ribavirin in difficult-to-treat hepatitis C virus (HCV) patients. The following studies will be reviewed in detail: (1) Sherman and colleagues conducted a study in 109 HCV RNA positive HVC patients comparing the combination of thymalfasin + IFN versus IFN alone versus placebo. (2) Rustgi et al. evaluated the efficacy and safety of thymalfasin and peg-IFN-α2a in 31 genotype 1, high viral load, HCV nonresponders in a 12-week viral kinetic study. (3) Di Bisceglie, Sherman et al. performed a study of previous HCV nonresponders being retreated with either peginterferon-α2a plus thymalfasin or peginterferon-α2a plus placebo. (4) Poo and colleagues in Mexico evaluated triple combination therapy using thymalfasin, peginterferon-α2a, and ribavirin for the treatment of Hispanic HCV nonresponders.

UR - http://www.scopus.com/inward/record.url?scp=35348980090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348980090&partnerID=8YFLogxK

U2 - 10.1196/annals.1415.034

DO - 10.1196/annals.1415.034

M3 - Conference contribution

SN - 1573317012

SN - 9781573317016

T3 - Annals of the New York Academy of Sciences

SP - 357

EP - 367

BT - Annals of the New York Academy of Sciences

PB - Blackwell Publishing Inc.

ER -

Rustgi V. Thymalfasin for the treatment of chronic hepatitis C infection. In Annals of the New York Academy of Sciences. Blackwell Publishing Inc. 2007. p. 357-367. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1415.034